Preferred Label : degarelix;
UMLS semantic type : T116 - Amino Acid, Peptide, or Protein;
Is substance : O;
Origin ID : M0470370;
UMLS CUI : C1455035;
Currated CISMeF NLP mapping
- Related record
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.ema.europa.eu/en/medicines/human/EPAR/degarelix-accord
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
degarelix
degarelix
degarelix
drugs, generic
---
https://www.has-sante.fr/jcms/p_3338772/fr/firmagon-degarelix-cancer-de-la-prostate
2022
France
evaluation of the transparency committee
neoplasm, malignant
prostatic neoplasms
malignant neoplasm prostate
degarelix
prostate cancer
prostatism, nos
prostate, nos
Prostate cancer
---
https://www.has-sante.fr/jcms/p_3242183/fr/firmagon
2021
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
degarelix
Degarelix Acetate
degarelix
injections, subcutaneous
hormone antagonists
prostatic neoplasms
neoplasms, hormone-dependent
advanced hormone-dependent prostate cancer
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
oligopeptides
---
https://www.cochrane.org/fr/CD012548/PROSTATE_le-degarelix-dans-le-cancer-avance-de-la-prostate-recemment-diagnostique
2021
United Kingdom
review of literature
french abstract
oligopeptides
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
diagnosis
Prostate cancer
neoplasm, malignant
recent
prostatism, nos
prostate, nos
prostatic neoplasms
degarelix
prostate cancer
malignant neoplasm prostate
---
http://conseil-scientifique.public.lu/fr/publications/oncologie/degarelix-mise-a-jour-2018.html
2018
false
false
true
Luxembourg
French
injections, subcutaneous
guidelines for drug use
degarelix
degarelix
gonadotropin-releasing hormone
hormone antagonists
neoplasms, hormone-dependent
prostatic neoplasms
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
oligopeptides
---
http://www.has-sante.fr/portail/jcms/c_2017117/fr/firmagon
http://www.has-sante.fr/portail/display.jsp?id=c_866783
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-02/firmagon_ct_6725.pdf
2015
false
France
French
Degarelix Acetate
advanced hormone-dependent prostate cancer
Hormone-dependent prostate cancer
Advanced Malignant Neoplasm
insurance, health, reimbursement
oligopeptides
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
degarelix
gonadotropin-releasing hormone
hormone antagonists
antineoplastic agents
injections, subcutaneous
prostatic neoplasms
neoplasms, hormone-dependent
treatment outcome
degarelix
evaluation of the transparency committee
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=63329030
2012
France
summary of product characteristics
package leaflet
powders
degarelix
injections
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=69784330
2012
France
summary of product characteristics
package leaflet
degarelix
injections
powders
---
https://www.ema.europa.eu/medicines/human/EPAR/Firmagon
2011
United Kingdom
French
English
syndication feed
hormone antagonists
hormone antagonists
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
prostatic neoplasms
oligopeptides
oligopeptides
gonadotropin-releasing hormone
neoplasms, hormone-dependent
injections, subcutaneous
treatment outcome
antineoplastic agents
antineoplastic agents
drug interactions
drug evaluation, preclinical
degarelix
degarelix
degarelix
drug evaluation
summary of product characteristics
package leaflet
---
Summary Basis of Decision FIRMAGON
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00063
2010
false
Canada
English
French
degarelix
degarelix
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
oligopeptides
oligopeptides
gonadotropin-releasing hormone
injections, subcutaneous
prostatic neoplasms
neoplasms, hormone-dependent
drug approval
degarelix
treatment outcome
hormone antagonists
hormone antagonists
drug information
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2009-10/firmagon_-_ct-6725.pdf
http://www.has-sante.fr/portail/jcms/c_928075/firmagon-degarelix-antagoniste-de-la-gnrh
2009
France
French
gonadotropin-releasing hormone
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
oligopeptides
insurance, health, reimbursement
degarelix
antineoplastic agents
injections, subcutaneous
treatment outcome
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
oligopeptides
prostatic neoplasms
neoplasms, hormone-dependent
antineoplastic agents
degarelix
degarelix
evaluation of the transparency committee
guidelines for drug use
---
